IMMP (IMMP) Stock Price & Analysis
IMMP (IMMP) fell 0.05% to USD 0.36 as of September 8, 2026 at 07:34 UTC, according to Nexqual real-time market data.
IMMP last closed at USD 0.37; the session ranged USD 0.36–0.38 on volume of 62,554 shares. Market capitalization is $53.78M, with a 52-week range of USD 0.29–3.53 (NGM). Source: Nexqual, September 8, 2026 at 07:34 UTC.
Key Statistics (as of September 8, 2026 at 07:34 UTC)
| Price | USD 0.36 |
|---|---|
| Change | ▼ 0.05% (down) |
| Previous Close | USD 0.37 |
| Open | USD 0.38 |
| Day Range | USD 0.36 – 0.38 |
| 52-Week Range | USD 0.29 – 3.53 |
| Volume | 62,554 shares |
| Market Cap | $53.78M |
| Exchange | NGM |
Technical Analysis (IMMP)
Nexqual's technical model rates IMMP "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 07:34 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.6 (neutral) |
| vs SMA50 | Below (USD 0.4) |
| MACD | -0.01 (negative) |
Analyst Ratings (IMMP)
Wall Street analysts rate IMMP "None" based on 1 analysts, with a mean price target of USD 1.5 (range USD 1.5–1.5), per Nexqual as of September 8, 2026 at 07:34 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 1.5 |
| High Target | USD 1.5 |
| Low Target | USD 1.5 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (IMMP)
| Next Earnings Date | 2026-09-03 |
|---|
Source: Nexqual, September 8, 2026 at 07:34 UTC.
Financials & Fundamentals (IMMP)
| Total Revenue | $19.93M |
|---|---|
| Revenue Growth (YoY) | +633.50% |
| Gross Margin | +0.00% |
| Operating Margin | -255.74% |
| Profit Margin | +0.00% |
| ROE | -77.31% |
| Debt / Equity | 1.7 |
| Current Ratio | 5.69 |
| Total Cash | $68.87M |
| Total Debt | $1.05M |
| Free Cash Flow | $-36.99M |
Source: Nexqual, September 8, 2026 at 07:34 UTC.
Financial Health Score (IMMP)
Nexqual rates IMMP's overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 07:34 UTC.
| Growth | Strong — Revenue +134% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $69M cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$37M, burning cash |
| Efficiency | Critical — ROE -77%, ROA -42.5% |
Ownership (IMMP)
| Insider Ownership | +0.01% |
|---|---|
| Institutional Ownership | +1.13% |
| Shares Outstanding | 147.37M |
| Float | 143.03M |
| Short % of Float | +0.53% |
Source: Nexqual, September 8, 2026 at 07:34 UTC.
Leadership (IMMP)
IMMP is led by Marc Voigt (age 52), CEO, MD, CFO, Chief Business Officer & Executive Director, per Nexqual as of September 8, 2026 at 07:34 UTC.
| CEO, MD, CFO, Chief Business Officer & Executive Director | Marc Voigt (age 52) |
|---|---|
| COO, General Counsel & Joint Company Secretary | Deanne Miller LLB (age 48) |
| Chief Scientific Officer & Executive Director | Frederic Triebel (age 70) |
Major Backers & Investors (IMMP)
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 1% |
| Vanguard Group | 0.24% |
Source: Nexqual, September 8, 2026 at 07:34 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GLSI | Greenwich LifeSciences, Inc. | USD 15.95 | ▲ 1.33% |
| XBIO | Xenetic Biosciences, Inc. | USD 4.67 | ▲ 9.88% |
| VTVT | vTv Therapeutics Inc. | USD 33.35 | ▼ 0.15% |
| ATHE | Alterity Therapeutics Limited | USD 4.54 | ▲ 0.44% |
| ENTX | Entera Bio Ltd. | USD 3 | ▲ 2.74% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:34 UTC. This page is informational and not investment advice.